维莫非尼治疗BRAFV600与非V600突变非小细胞肺癌
AcSé维莫非尼试验NSCLC队列纳入118例BRAF突变NSCLC患者,其中101例BRAFV600、17例BRAF非V600。BRAFV600队列客观缓解率44.9%(95%CI 35.2%-54.8%),中位PFS 5.2个月、OS 10个月;BRAF非V600队列无客观缓解而终止。
要点
- BRAFV600突变NSCLC患者可从维莫非尼单药治疗中获益
- BRAF非V600突变NSCLC患者未观察到客观缓解
- NSCLC常规生物标志物筛查应纳入BRAFV600突变
核心结论
- 维莫非尼单药对BRAFV600突变NSCLC有效,对BRAF非V600突变NSCLC无效。
研究设计与样本
- 法国国家癌症研究所发起的AcSé维莫非尼试验NSCLC队列,2014年10月至2018年7月入组118例经≥1线治疗进展的BRAF突变NSCLC患者。
主要发现
- BRAF非V600队列17例未观察到客观缓解,该队列终止。
- BRAFV600队列96例中43例客观缓解,贝叶斯估计成功率44.9%(95%CI 35.2%-54.8%)。
- ORR达到≥30%的概率为99.9%,中位缓解持续时间6.4个月。
- 中位PFS为5.2个月(95%CI 3.8-6.8),OS为10个月(95%CI 6.8-15.7)。
- 维莫非尼安全性特征与既往发表一致。
关键数值与推荐
- BRAF突变在NSCLC中发生率为1%-5%。
- 维莫非尼剂量为960 mg每日两次。
- 疗效每8周按RECIST v1.1评估,贝叶斯无效性界值为ORR 10%,若估计ORR≥30%且概率达90%则治疗有意义。
临床怎么用
- NSCLC常规生物标志物筛查应包含BRAFV600突变以筛选维莫非尼治疗获益人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: BRAF mutations occurring in 1%-5% of patients with non-small-cell lung cancer (NSCLC) are therapeutic targets for these cancers but the impact of the exact mutation on clinical activity is unclear. The French National Cancer Institute (INCA) launched the AcSé vemurafenib trial to assess the efficacy and safety of vemurafenib in cancers with various BRAF mutations. We herein report the results of the NSCLC cohort. PATIENTS AND METHODS: Tumour samples were screened for BRAF mutations in INCA-certified molecular genetic centres. Patients with BRAF-mutated tumours progressing after ≥1 line of treatment were proposed vemurafenib 960 mg twice daily. Between October 2014 and July 2018, 118 patients were enrolled in the NSCLC cohort. The primary outcome was the objective response rate (ORR) assessed every 8 weeks (RECIST v1.1). A sequential Bayesian approach was planned with an inefficacy bound of 10% for ORR. If no early stopping occurred, the treatment was of interest if the estimated ORR was ≥30% with a 90% probability. Secondary outcomes were tolerance, response duration, progression-free survival (PFS), and overall survival (OS). RESULTS: Of the 118 patients enrolled, 101 presented with a BRAFV600 mutation and 17 with BRAFnonV600 mutations; the median follow-up was 23.9 months. In the BRAFnonV600 cohort, no objective response was observed and this cohort was stopped. In the BRAFV600 cohort, 43/96 patients had objective responses. The mean Bayesian estimated success rate was 44.9% [95% confidence intervals (CI) 35.2%-54.8%]. The ORR had a 99.9% probability of being ≥30%. Median response duration was 6.4 months, median PFS was 5.2 months (95% CI 3.8-6.8), and OS was 10 months (95% CI 6.8-15.7). The vemurafenib safety profile was consistent with previous publications. CONCLUSION: Routine biomarker screening of NSCLC should include BRAFV600 mutations. Vemurafenib monotherapy is effective for treating patients with BRAFV600-mutated NSCLC but not those with BRAFnonV600 mutations. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02304809.
引用
- Mazieres J, Cropet C, Montané L, et al. Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. Ann Oncol. 2020. PMID: 31959346. doi:10.1016/j.annonc.2019.10.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。